FR09C0021I2 - Anticorps, compositions, procedes anti-il-12 et leur utilisation - Google Patents
Anticorps, compositions, procedes anti-il-12 et leur utilisationInfo
- Publication number
- FR09C0021I2 FR09C0021I2 FR09C0021C FR09C0021C FR09C0021I2 FR 09C0021 I2 FR09C0021 I2 FR 09C0021I2 FR 09C0021 C FR09C0021 C FR 09C0021C FR 09C0021 C FR09C0021 C FR 09C0021C FR 09C0021 I2 FR09C0021 I2 FR 09C0021I2
- Authority
- FR
- France
- Prior art keywords
- antibodies
- compositions
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22335800P | 2000-08-07 | 2000-08-07 | |
US23682700P | 2000-09-29 | 2000-09-29 | |
US09/920,262 US6902734B2 (en) | 2000-08-07 | 2001-08-01 | Anti-IL-12 antibodies and compositions thereof |
PCT/US2001/024720 WO2002012500A2 (fr) | 2000-08-07 | 2001-08-07 | Anticorps, compositions, procedes anti-il-12 et leur utilisation |
Publications (2)
Publication Number | Publication Date |
---|---|
FR09C0021I1 FR09C0021I1 (fr) | 2009-09-25 |
FR09C0021I2 true FR09C0021I2 (fr) | 2010-06-11 |
Family
ID=27397221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR09C0021C Active FR09C0021I2 (fr) | 2000-08-07 | 2009-05-13 | Anticorps, compositions, procedes anti-il-12 et leur utilisation |
Country Status (33)
Country | Link |
---|---|
US (15) | US6902734B2 (fr) |
EP (5) | EP2090657B1 (fr) |
JP (4) | JP4731094B2 (fr) |
KR (1) | KR100823576B1 (fr) |
CN (2) | CN101550190B (fr) |
AR (1) | AR030134A1 (fr) |
AT (1) | ATE431412T1 (fr) |
AU (2) | AU8113701A (fr) |
BR (1) | BRPI0113109B8 (fr) |
CA (1) | CA2418961C (fr) |
CL (1) | CL2009000575A1 (fr) |
CY (7) | CY1109149T1 (fr) |
DE (2) | DE60138711D1 (fr) |
DK (4) | DK2090657T3 (fr) |
EA (1) | EA006673B1 (fr) |
ES (4) | ES2647220T3 (fr) |
FR (1) | FR09C0021I2 (fr) |
HK (1) | HK1135991A1 (fr) |
HR (1) | HRP20030087B1 (fr) |
HU (1) | HU228009B1 (fr) |
IL (1) | IL154325A (fr) |
LT (6) | LT2090657T (fr) |
LU (3) | LU91584I2 (fr) |
ME (1) | ME00326B (fr) |
MX (1) | MXPA03001229A (fr) |
MY (1) | MY133377A (fr) |
NL (1) | NL300390I2 (fr) |
NO (3) | NO330903B1 (fr) |
NZ (2) | NZ524145A (fr) |
PT (4) | PT2090657T (fr) |
RS (1) | RS50477B (fr) |
SI (4) | SI2305817T1 (fr) |
WO (1) | WO2002012500A2 (fr) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US6706264B1 (en) * | 1994-03-14 | 2004-03-16 | Genetics Institute, Llc | Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
US7883704B2 (en) | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
US6902734B2 (en) * | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
US20050249735A1 (en) * | 2000-08-07 | 2005-11-10 | Centocor, Inc. | Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor |
AU2003220557A1 (en) * | 2002-03-26 | 2003-10-13 | Centocor, Inc. | Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses |
AU2003218432A1 (en) * | 2002-03-26 | 2003-10-13 | Centocor, Inc. | Diabetes-related immunoglobulin derived proteins, compositions, methods and uses |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
CN101824088B (zh) * | 2002-10-30 | 2012-05-30 | 健泰科生物技术公司 | Il-17产生的抑制 |
US20070178082A1 (en) * | 2002-11-08 | 2007-08-02 | Ablynx N.V. | Stabilized single domain antibodies |
US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
US20060034845A1 (en) * | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
US20100003253A1 (en) * | 2002-11-08 | 2010-01-07 | Ablynx N.V. | Single domain antibodies directed against epidermal growth factor receptor and uses therefor |
EP2258392A1 (fr) * | 2002-11-08 | 2010-12-08 | Ablynx N.V. | Procédé d'administration de polypeptides thérapeutiques |
TWI395756B (zh) * | 2003-07-18 | 2013-05-11 | Amgen Inc | 對肝細胞生長因子具專一性之結合劑 |
GB0329146D0 (en) * | 2003-12-16 | 2004-01-21 | Glaxosmithkline Biolog Sa | Vaccine |
NZ548897A (en) * | 2004-02-17 | 2009-07-31 | Schering Corp | Methods of modulating IL-23 activity; related reagents |
AR051805A1 (es) | 2004-12-21 | 2007-02-07 | Centocor Inc | Anticuerpos anti-il-12, epitopos, composiciones, metodos y usos |
US7736650B2 (en) * | 2004-12-21 | 2010-06-15 | Centocor, Inc. | Anti-IL-12 antibody based vectors, host cells, and methods of production and uses |
US7785595B2 (en) | 2005-04-18 | 2010-08-31 | Yeda Research And Development Company Limited | Stabilized anti-hepatitis B (HBV) antibody formulations |
CN103145838A (zh) * | 2005-06-30 | 2013-06-12 | Abbvie公司 | Il-12/p40结合蛋白 |
JP2007172129A (ja) * | 2005-12-20 | 2007-07-05 | Sony Corp | 不揮発性メモリアクセス制御装置および不揮発性メモリ制御システム |
WO2007137328A1 (fr) * | 2006-05-26 | 2007-12-06 | Apollo Life Sciences Limited | Molécule il-12 isolée ou sa molécule chimérique |
WO2008070647A1 (fr) * | 2006-12-07 | 2008-06-12 | Wyeth | Procédés et compositions permettant d'évaluer l'il-12 ou la neutralisation de l'il-12 dans un échantillon |
KR20090100461A (ko) | 2007-01-16 | 2009-09-23 | 아보트 러보러터리즈 | 건선의 치료방법 |
CA2681752A1 (fr) * | 2007-03-29 | 2008-10-09 | Abbott Laboratories | Anticorps anti-1l-12 humains cristallins |
US20090181027A1 (en) * | 2007-09-28 | 2009-07-16 | Paul Dal Monte | Anti-IL-12/23p40 Antibodies, Epitopes, Formulations, Compositions, Methods and Uses |
MX2010005783A (es) | 2007-11-27 | 2010-08-10 | Ablynx Nv | Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas. |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
SG188909A1 (en) | 2008-03-18 | 2013-04-30 | Abbott Lab | Methods for treating psoriasis |
NZ600584A (en) * | 2008-05-05 | 2014-05-30 | Novimmune Sa | Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof |
JP5856845B2 (ja) | 2008-10-20 | 2016-02-10 | アッヴィ・インコーポレイテッド | 抗体精製中におけるウイルスの不活性化 |
BRPI0919547A2 (pt) * | 2008-10-20 | 2015-12-08 | Abbott Lab | anticorpos que se ligam a il-12 e métodos de purificação do mesmo |
KR20110096553A (ko) * | 2008-11-28 | 2011-08-30 | 아보트 러보러터리즈 | 안정한 항체 조성물 및 이의 안정화 방법 |
MX2011011729A (es) | 2009-05-05 | 2012-04-10 | Novimmune Sa | Anticuerpo anti il-17f y metodos de uso de los mismos. |
KR20120112384A (ko) * | 2009-09-14 | 2012-10-11 | 애보트 게엠베하 운트 콤파니 카게 | 건선을 치료하는 방법 |
EP2552967A4 (fr) | 2010-04-02 | 2014-10-08 | Amunix Operating Inc | Protéines de fusion liantes, conjugués protéines de fusion liantes-médicaments, conjugués xten-médicaments et procédés pour les préparer et les utiliser |
WO2012019168A2 (fr) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Acides nucléiques modifiés et leurs procédés d'utilisation |
US20120237975A1 (en) | 2010-10-01 | 2012-09-20 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
TW201309330A (zh) * | 2011-01-28 | 2013-03-01 | Abbott Lab | 包含糖基化抗體之組合物及其用途 |
CA2831613A1 (fr) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Administration et formulation d'acides nucleiques genetiquement modifies |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP4015005A1 (fr) | 2011-10-03 | 2022-06-22 | ModernaTX, Inc. | Nucléosides, nucléotides et acides nucléiques modifiés et leurs utilisations |
SG11201402666WA (en) | 2011-12-16 | 2014-10-30 | Moderna Therapeutics Inc | Modified nucleoside, nucleotide, and nucleic acid compositions |
EP2791172B1 (fr) | 2011-12-16 | 2017-07-19 | Synthon Biopharmaceuticals B.V. | Composés et méthodes de traitement de maladies inflammatoires |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
AU2013243955B2 (en) | 2012-04-02 | 2018-02-22 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
CA2872908C (fr) * | 2012-05-10 | 2023-11-14 | Gerhard Frey | Anticorps monoclonaux multi-specifiques |
ES2729603T3 (es) | 2012-06-27 | 2019-11-05 | Merck Sharp & Dohme | Anticuerpos IL-23 antihumanos cristalinos |
PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US9603775B2 (en) | 2013-04-24 | 2017-03-28 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
WO2015048744A2 (fr) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucléotides codant des polypeptides de modulation immunitaire |
CN105980401A (zh) | 2013-10-03 | 2016-09-28 | 现代治疗公司 | 编码低密度脂蛋白受体的多核苷酸 |
WO2016036918A1 (fr) | 2014-09-03 | 2016-03-10 | Boehringer Ingelheim International Gmbh | Composé ciblant il-23a et tnf-alpha, et ses utilisations |
WO2016172359A2 (fr) * | 2015-04-24 | 2016-10-27 | The Regents Of The University Of California | Systèmes de détection, de contrôle ou de traitement de maladies ou d'états utilisant des cellules génétiquement modifiées et leurs procédés de fabrication et d'utilisation |
CN115636880A (zh) * | 2015-10-23 | 2023-01-24 | 辉瑞有限公司 | 抗il-2抗体及其组合物和用途 |
CN109071653A (zh) * | 2016-03-29 | 2018-12-21 | 詹森生物科技公司 | 用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣 |
WO2018024770A1 (fr) | 2016-08-03 | 2018-02-08 | Formycon Ag | Production d'ustekinumab biosimilaire dans des cellules cho |
JP2020502261A (ja) * | 2016-11-16 | 2020-01-23 | ヤンセン バイオテツク,インコーポレーテツド | 抗il23特異的抗体で乾癬を治療する方法 |
WO2018106931A1 (fr) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Procédés, dispositifs et systèmes de détection du tractus gastro-intestinal |
WO2018112232A1 (fr) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur des interleukines il-12/il-23 libéré à l'aide d'un dispositif ingérable |
EP3573658A4 (fr) | 2017-01-30 | 2021-07-21 | Janssen Biotech, Inc. | Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif |
KR20190115042A (ko) | 2017-02-07 | 2019-10-10 | 얀센 바이오테크 인코포레이티드 | 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법 |
EP3635093A1 (fr) | 2017-06-08 | 2020-04-15 | Polpharma Biologics S.A. | Méthodes améliorées de culture cellulaire |
TW201922780A (zh) * | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗il12/il23抗體治療狼瘡之安全且有效之方法 |
WO2019106206A1 (fr) | 2017-12-01 | 2019-06-06 | Fyb 202 Project Gmbh | Formulations liquides stables, à faible viscosité et à haute concentration en un anticorps anti-il-12/23p40 |
EP3793521A4 (fr) | 2018-05-18 | 2022-02-23 | Janssen Biotech, Inc. | Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23 |
TR201808283A2 (tr) * | 2018-06-11 | 2018-07-23 | Centurion Ilac San Ve Tic A S | Sulu farmasöti̇k etenersept bi̇leşi̇mi̇ |
WO2019246317A1 (fr) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Traitement d'une maladie ou d'un état dans un tissu provenant de l'endoderme |
WO2019246271A1 (fr) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur d'il-12/il-23 |
US20200061015A1 (en) | 2018-08-23 | 2020-02-27 | Janssen Biotech, Inc. | Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations |
LT3883606T (lt) | 2018-09-24 | 2023-09-11 | Janssen Biotech, Inc. | Saugus ir veiksmingas opinio kolito gydymo būdas anti-il12/il23 antikūnu |
CN116726361A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
BR112021009287A2 (pt) | 2018-11-20 | 2021-10-26 | Janssen Biotech, Inc. | Método seguro e eficaz para tratar psoríase com anticorpo específico anti-il-23 |
AU2020208828A1 (en) | 2019-01-15 | 2021-08-05 | Janssen Biotech, Inc. | Anti-TNF antibody compositions and methods for the treatment of juvenile idiopathic arthritis |
EP3914618A1 (fr) | 2019-01-23 | 2021-12-01 | Janssen Biotech, Inc. | Compositions d'anticorps anti-tnf destinées à être utilisées dans des méthodes de traitement d'arthrite psoriasique |
MA55283A (fr) | 2019-03-14 | 2022-01-19 | Janssen Biotech Inc | Procédés de production de compositions d'anticorps anti-tnf |
EP3938390A1 (fr) | 2019-03-14 | 2022-01-19 | Janssen Biotech, Inc. | Procédés de fabrication pour la production de compositions d'anticorps anti-tnf |
CN113840837A (zh) | 2019-03-14 | 2021-12-24 | 詹森生物科技公司 | 用于产生抗tnf抗体组合物的方法 |
JP2022526493A (ja) * | 2019-03-18 | 2022-05-25 | ヤンセン バイオテツク,インコーポレーテツド | 抗il12/il23抗体を用いた小児被験者の乾癬の治療方法 |
EP3972690A4 (fr) | 2019-05-23 | 2023-07-05 | Janssen Biotech, Inc. | Méthode de traitement de maladie intestinale inflammatoire au moyen d'une polythérapie d'anticorps dirigés contre il -23 et tnf alpha |
EP3976648A1 (fr) | 2019-06-03 | 2022-04-06 | Janssen Biotech, Inc. | Compositions d'anticorps anti-tnf et méthodes pour le traitement de l'arthrite psoriasique |
MX2021014882A (es) | 2019-06-03 | 2022-03-25 | Janssen Biotech Inc | Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa. |
CN112079922B (zh) * | 2019-07-30 | 2022-08-12 | 中山康方生物医药有限公司 | 抗人p40蛋白域抗体及其用途 |
WO2021028752A1 (fr) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anticorps anti-tfn pour le traitement du diabète de type i |
EP3870261B1 (fr) | 2019-12-13 | 2024-01-31 | Biora Therapeutics, Inc. | Dispositif ingestible pour la livraison d'un agent thérapeutique au système gastro-intestinal |
CN115135671A (zh) | 2019-12-20 | 2022-09-30 | 新石生物制药有限公司 | 抗白介素-23 p19的抗体及其使用方法 |
AU2021315081A1 (en) * | 2020-07-30 | 2023-03-30 | Janssen Biotech, Inc. | Method of treating psoriasis in pediatric subjects with anti-IL12/IL23 antibody |
US20230040065A1 (en) | 2021-07-09 | 2023-02-09 | Janssen Biotech, Inc. | Manufacturing Methods for Producing Anti-TNF Antibody Compositions |
WO2023281463A1 (fr) | 2021-07-09 | 2023-01-12 | Janssen Biotech, Inc. | Procédés de fabrication pour produire des compositions d'anticorps anti-tnf |
US20240117030A1 (en) | 2022-03-03 | 2024-04-11 | Pfizer Inc. | Multispecific antibodies and uses thereof |
US20240059799A1 (en) | 2022-05-11 | 2024-02-22 | Pfizer Inc. | Anti-tl1a antibodies and methods of use thereof |
Family Cites Families (179)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US122464A (en) | 1872-01-02 | Improvement in cheese-hoops | ||
US941234A (en) | 1909-02-25 | 1909-11-23 | Frank De Clercq | Syrup-percolator. |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4309989A (en) | 1976-02-09 | 1982-01-12 | The Curators Of The University Of Missouri | Topical application of medication by ultrasound with coupling agent |
FR2374910A1 (fr) | 1976-10-23 | 1978-07-21 | Choay Sa | Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
US5149636A (en) | 1982-03-15 | 1992-09-22 | Trustees Of Columbia University In The City Of New York | Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
DE3590766T (fr) | 1985-03-30 | 1987-04-23 | ||
SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
US4766067A (en) | 1985-05-31 | 1988-08-23 | President And Fellows Of Harvard College | Gene amplification |
GB8517895D0 (en) | 1985-07-16 | 1985-08-21 | Technology Licence Co Ltd | Monoclonal antibodies |
US4870163A (en) | 1985-08-29 | 1989-09-26 | New York Blood Center, Inc. | Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5576195A (en) | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
SE453566B (sv) | 1986-03-07 | 1988-02-15 | Draco Ab | Anordning vid pulverinhalatorer |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
JP2876058B2 (ja) | 1986-08-18 | 1999-03-31 | エミスフィア・テクノロジーズ・インコーポレイテッド | 薬物送達システム |
US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
US5763192A (en) | 1986-11-20 | 1998-06-09 | Ixsys, Incorporated | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
US4795699A (en) | 1987-01-14 | 1989-01-03 | President And Fellows Of Harvard College | T7 DNA polymerase |
US4921794A (en) | 1987-01-14 | 1990-05-01 | President And Fellows Of Harvard College | T7 DNA polymerase |
EP0279582A3 (fr) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Séquences d'ADN pour diriger des protéines vers les glandes mammaires afin d'être sécrétées efficacement |
DE3852304T3 (de) | 1987-03-02 | 1999-07-01 | Enzon Labs Inc., Piscataway, N.J. | Organismus als Träger für "Single Chain Antibody Domain (SCAD)". |
EP0288088B1 (fr) | 1987-04-24 | 1994-03-09 | Teijin Limited | Détection du facteur nécrosant de tumeur; anticorps monoclonal et composition |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
CA1341235C (fr) | 1987-07-24 | 2001-05-22 | Randy R. Robinson | Assemblage modulaire de genes d'anticorps, anticorps prepares de cette facon, ainsi que leur usage |
US4939666A (en) | 1987-09-02 | 1990-07-03 | Genex Corporation | Incremental macromolecule construction methods |
ES2058199T3 (es) | 1987-09-23 | 1994-11-01 | Bristol Myers Squibb Co | Heteroconjugados de anticuerpos para la eliminacion de celulas infectadas por el vih. |
ATE140731T1 (de) | 1988-01-11 | 1996-08-15 | Xoma Corp | Plasmidvektor mit pectatlyase-signalsequenz |
US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5091310A (en) | 1988-09-23 | 1992-02-25 | Cetus Corporation | Structure-independent dna amplification by the polymerase chain reaction |
US5142033A (en) | 1988-09-23 | 1992-08-25 | Hoffmann-La Roche Inc. | Structure-independent DNA amplification by the polymerase chain reaction |
US5066584A (en) | 1988-09-23 | 1991-11-19 | Cetus Corporation | Methods for generating single stranded dna by the polymerase chain reaction |
US4987893A (en) | 1988-10-12 | 1991-01-29 | Rochal Industries, Inc. | Conformable bandage and coating material |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5457038A (en) | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
ATE140483T1 (de) | 1988-11-10 | 1996-08-15 | Genetics Inst | Natürlicher killerzellen-stimulationsfaktor |
US5811523A (en) | 1988-11-10 | 1998-09-22 | Trinchieri; Giorgio | Antibodies to natural killer stimulatory factor |
DE68913658T3 (de) | 1988-11-11 | 2005-07-21 | Stratagene, La Jolla | Klonierung von Immunglobulin Sequenzen aus den variablen Domänen |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US4994370A (en) | 1989-01-03 | 1991-02-19 | The United States Of America As Represented By The Department Of Health And Human Services | DNA amplification technique |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
DE3909708A1 (de) | 1989-03-23 | 1990-09-27 | Boehringer Mannheim Gmbh | Verfahren zur herstellung bispezifischer antikoerper |
AU652539B2 (en) | 1989-05-16 | 1994-09-01 | Medical Research Council | Co-expression of heteromeric receptors |
CA2016842A1 (fr) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Methode pour puiser dans le repertoire immunologique |
CA2016841C (fr) | 1989-05-16 | 1999-09-21 | William D. Huse | Methode de production de polymeres ayant une activite choisie |
WO1991000360A1 (fr) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Reactifs bispecifiques pour le traitement du sida |
DE10399036I1 (de) | 1989-08-07 | 2004-04-01 | Peptide Technology Ltd | Bindeligande für Tumornekrosisfaktor. |
ES2118066T3 (es) | 1989-10-05 | 1998-09-16 | Optein Inc | Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos. |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
ATE369383T1 (de) | 1989-12-22 | 2007-08-15 | Hoffmann La Roche | Monoklonale antikörper spezifisch für den zytotoxischen lymphozyten-reifefaktor |
US5780597A (en) | 1989-12-22 | 1998-07-14 | Hoffmann-La Roche Inc. | Monoclonal antibodies to cytotoxic lymphocyte maturation factor |
ES2087997T3 (es) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | Generacion de anticuerpos xenogenicos. |
TW212184B (fr) | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
ATE160818T1 (de) | 1990-06-01 | 1997-12-15 | Chiron Corp | Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
JPH06500011A (ja) | 1990-06-29 | 1994-01-06 | ラージ スケール バイオロジー コーポレイション | 形質転換された微生物によるメラニンの製造 |
US5580734A (en) | 1990-07-13 | 1996-12-03 | Transkaryotic Therapies, Inc. | Method of producing a physical map contigous DNA sequences |
CA2090126C (fr) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methodes de production de proteines dotees d'une fonction desiree |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1992005258A1 (fr) | 1990-09-20 | 1992-04-02 | La Trobe University | Gene encodant une enzyme de l'orge |
GB9022648D0 (en) | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
JPH06508022A (ja) | 1991-02-21 | 1994-09-14 | ギリアド サイエンシズ,インコーポレイテッド | 生体分子に特異的なアプタマーおよび生産方法 |
US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
ES2199935T3 (es) | 1991-03-15 | 2004-03-01 | Amgen Inc. | Pegilacion de polipeptidos. |
DE69233367T2 (de) | 1991-04-10 | 2005-05-25 | The Scripps Research Institute, La Jolla | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
WO1992020373A1 (fr) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Anticorps d'heteroconjugues pour le traitement des infections a l'hiv |
DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
ATE189124T1 (de) | 1991-07-02 | 2000-02-15 | Inhale Inc | Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
WO1993008829A1 (fr) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions induisant la destruction de cellules infectees par l'hiv |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5733761A (en) | 1991-11-05 | 1998-03-31 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
CA2507749C (fr) | 1991-12-13 | 2010-08-24 | Xoma Corporation | Methodes et materiaux pour la preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
DE4207475A1 (de) | 1992-03-10 | 1993-09-16 | Goldwell Ag | Mittel zum blondieren von menschlichen haaren und verfahren zu dessen herstellung |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
AU4829593A (en) | 1992-09-23 | 1994-04-12 | Fisons Plc | Inhalation device |
WO1994008038A1 (fr) | 1992-10-02 | 1994-04-14 | Trustees Of Dartmouth College | Agents bispecifiques de reorientation du ciblage des lipoproteines de faible densite |
BR9307270A (pt) | 1992-10-19 | 1999-06-01 | Dura Pharma Inc | Inalador de pó seco |
US5643252A (en) | 1992-10-28 | 1997-07-01 | Venisect, Inc. | Laser perforator |
WO1994012520A1 (fr) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Segment de liaison pour polypeptides fusionnes lies |
US5849695A (en) | 1993-01-13 | 1998-12-15 | The Regents Of The University Of California | Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals |
EP0680451B1 (fr) | 1993-01-19 | 1998-11-04 | Glaxo Group Limited | BOMBE AEROSOLE ET PROCéDé DE LA FABRICATION |
US5300478A (en) * | 1993-01-28 | 1994-04-05 | Zeneca Limited | Substituted fused pyrazolo compounds |
EP1978095A1 (fr) | 1993-02-12 | 2008-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Transcription régulée de gènes ciblés et autres évènements biologiques |
EP0614989A1 (fr) | 1993-02-17 | 1994-09-14 | MorphoSys AG | Procédé de sélection in vivo des protéines attachées des ligands |
US5770428A (en) | 1993-02-17 | 1998-06-23 | Wisconsin Alumni Research Foundation | Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site |
AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2113101T3 (es) * | 1993-04-30 | 1998-04-16 | Tokyo Tanabe Co | Metodo para purificar polipeptidos hidrofobos. |
DE4315127A1 (de) | 1993-05-07 | 1994-11-10 | Behringwerke Ag | Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12 |
CA2125763C (fr) * | 1993-07-02 | 2007-08-28 | Maurice Kent Gately | Homodimere p40 de l'interleukine-12 |
US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
DE4337197C1 (de) | 1993-10-30 | 1994-08-25 | Biotest Pharma Gmbh | Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore |
US5814599A (en) | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
SE9304060D0 (sv) | 1993-12-06 | 1993-12-06 | Bioinvent Int Ab | Sätt att selektera specifika bakteriofager |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
CA2183268C (fr) | 1994-03-07 | 2001-05-15 | Edward D. Ball | Molecules bispecifiques se pretant a des applications cliniques |
ZA95960B (en) | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
DE69522965T2 (de) | 1994-04-22 | 2002-04-04 | Corixa Corp., Seattle | Verbindungen und methoden für die stimulierungen und die erhöhung von schutzimmunantworten und il-12 herstellung |
US5763733A (en) | 1994-10-13 | 1998-06-09 | Enzon, Inc. | Antigen-binding fusion proteins |
US5549551A (en) | 1994-12-22 | 1996-08-27 | Advanced Cardiovascular Systems, Inc. | Adjustable length balloon catheter |
US6086875A (en) * | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US5891680A (en) | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6037453A (en) | 1995-03-15 | 2000-03-14 | Genentech, Inc. | Immunoglobulin variants |
US5656730A (en) | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
KR100654645B1 (ko) * | 1995-04-27 | 2007-04-04 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
CA2219486A1 (fr) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Anticorps humains derives de xeno-souris immunisees |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
US5853697A (en) | 1995-10-25 | 1998-12-29 | The United States Of America, As Represented By The Department Of Health & Human Services | Methods of treating established colitis using antibodies against IL-12 |
GB9526100D0 (en) | 1995-12-20 | 1996-02-21 | Intersurgical Ltd | Nebulizer |
ES2167987T3 (es) | 1996-01-03 | 2002-05-16 | Glaxo Group Ltd | Dispositivo inhalador. |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
DE19624387C2 (de) | 1996-06-19 | 1999-08-19 | Hatz Motoren | Kaltstartvorrichtung |
ES2169299T3 (es) | 1996-09-03 | 2002-07-01 | Gsf Forschungszentrum Umwelt | Procedimiento para la destruccion de celulas tumorales contaminantes en transplantes de celulas madre utilizando anticuerpos especificos. |
CA2722378C (fr) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Anticorps humains qui se lient au tnf.alpha. |
WO1998034635A1 (fr) | 1997-02-07 | 1998-08-13 | The Wistar Institute | Procedes et compositions pour inhiber la production d'interleukine 12 |
US5879681A (en) | 1997-02-07 | 1999-03-09 | Emisphere Technolgies Inc. | Compounds and compositions for delivering active agents |
US5921447A (en) | 1997-02-13 | 1999-07-13 | Glaxo Wellcome Inc. | Flow-through metered aerosol dispensing apparatus and method of use thereof |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
IL120943A (en) | 1997-05-29 | 2004-03-28 | Univ Ben Gurion | A system for administering drugs through the skin |
US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
CN100374466C (zh) | 1998-01-23 | 2008-03-12 | 霍夫曼-拉罗奇有限公司 | 人il-12抗体 |
ES2251248T3 (es) | 1998-12-09 | 2006-04-16 | Protein Design Labs, Inc. | Uso de anticuerpos contra il-12 para tratar la psoriasis. |
US6914128B1 (en) * | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
BR0009323A (pt) | 1999-03-25 | 2002-01-08 | Knoll Gmbh | Anticorpos humanos que ligam a il-12 humana e métodos para a produção |
WO2001019373A2 (fr) | 1999-09-17 | 2001-03-22 | Basf Aktiengesellschaft | Procedes et compositions permettant de moduler la sensibilite aux corticosteroides |
US6902734B2 (en) * | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
US20040014198A1 (en) | 2002-05-23 | 2004-01-22 | Craft David L. | Non-revertible beta-oxidation blocked candida tropicalis |
DE102007030072A1 (de) | 2007-06-29 | 2009-01-02 | BSH Bosch und Siemens Hausgeräte GmbH | Elektrischen Antriebseinrichtung für ein Wasserführendes Haushaltsgerät |
JP5470817B2 (ja) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | 電池用電極およびこれを用いた電池、並びにその製造方法 |
JP5155355B2 (ja) | 2010-04-07 | 2013-03-06 | レノボ・シンガポール・プライベート・リミテッド | 無線基地局の自律的な負荷調整が可能な無線端末装置 |
US9619256B1 (en) | 2012-06-27 | 2017-04-11 | EMC IP Holding Company LLC | Multi site and multi tenancy |
JP6136279B2 (ja) | 2013-01-15 | 2017-05-31 | 株式会社ジェイテクト | 転がり軸受装置 |
TWI503850B (zh) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | 過電流保護元件 |
TWI510996B (zh) | 2013-10-03 | 2015-12-01 | Acer Inc | 控制觸控面板的方法以及使用該方法的可攜式電腦 |
US9205258B2 (en) | 2013-11-04 | 2015-12-08 | ElectroCore, LLC | Nerve stimulator system |
US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
-
2001
- 2001-08-01 US US09/920,262 patent/US6902734B2/en not_active Expired - Lifetime
- 2001-08-07 PT PT90063967T patent/PT2090657T/pt unknown
- 2001-08-07 ES ES10184116.1T patent/ES2647220T3/es not_active Expired - Lifetime
- 2001-08-07 PT PT01959598T patent/PT1309692E/pt unknown
- 2001-08-07 BR BRPI0113109A patent/BRPI0113109B8/pt active IP Right Grant
- 2001-08-07 DE DE60138711T patent/DE60138711D1/de not_active Expired - Lifetime
- 2001-08-07 EP EP09006396.7A patent/EP2090657B1/fr not_active Expired - Lifetime
- 2001-08-07 AU AU8113701A patent/AU8113701A/xx active Pending
- 2001-08-07 RS YUP-93/03A patent/RS50477B/sr unknown
- 2001-08-07 LT LTEP09006396.7T patent/LT2090657T/lt unknown
- 2001-08-07 CN CN200810100025.3A patent/CN101550190B/zh not_active Expired - Lifetime
- 2001-08-07 ME MEP-2008-444A patent/ME00326B/fr unknown
- 2001-08-07 JP JP2002517788A patent/JP4731094B2/ja not_active Expired - Lifetime
- 2001-08-07 ES ES17153336T patent/ES2747573T3/es not_active Expired - Lifetime
- 2001-08-07 PT PT171533367T patent/PT3178934T/pt unknown
- 2001-08-07 DE DE122009000025C patent/DE122009000025I1/de active Pending
- 2001-08-07 LT LTEP17153336.7T patent/LT3178934T/lt unknown
- 2001-08-07 ES ES01959598T patent/ES2323760T3/es not_active Expired - Lifetime
- 2001-08-07 DK DK09006396.7T patent/DK2090657T3/en active
- 2001-08-07 SI SI200131066T patent/SI2305817T1/en unknown
- 2001-08-07 DK DK17153336.7T patent/DK3178934T3/da active
- 2001-08-07 EA EA200300137A patent/EA006673B1/ru not_active IP Right Cessation
- 2001-08-07 MY MYPI20013706 patent/MY133377A/en unknown
- 2001-08-07 CN CNA018169619A patent/CN1468309A/zh active Pending
- 2001-08-07 DK DK10184116.1T patent/DK2305817T3/en active
- 2001-08-07 AU AU2001281137A patent/AU2001281137B2/en not_active Expired
- 2001-08-07 HU HU0302378A patent/HU228009B1/hu active Protection Beyond IP Right Term
- 2001-08-07 PT PT101841161T patent/PT2305817T/pt unknown
- 2001-08-07 EP EP19179253.0A patent/EP3597752A1/fr not_active Withdrawn
- 2001-08-07 WO PCT/US2001/024720 patent/WO2002012500A2/fr active IP Right Grant
- 2001-08-07 SI SI200130913T patent/SI1309692T1/sl unknown
- 2001-08-07 AT AT01959598T patent/ATE431412T1/de active
- 2001-08-07 ES ES09006396.7T patent/ES2624502T3/es not_active Expired - Lifetime
- 2001-08-07 AR ARP010103780A patent/AR030134A1/es active IP Right Grant
- 2001-08-07 SI SI200131060A patent/SI2090657T1/sl unknown
- 2001-08-07 KR KR1020037001843A patent/KR100823576B1/ko active Protection Beyond IP Right Term
- 2001-08-07 NZ NZ524145A patent/NZ524145A/en not_active IP Right Cessation
- 2001-08-07 LT LTEP10184116.1T patent/LT2305817T/lt unknown
- 2001-08-07 IL IL154325A patent/IL154325A/en active Protection Beyond IP Right Term
- 2001-08-07 DK DK01959598T patent/DK1309692T3/da active
- 2001-08-07 MX MXPA03001229A patent/MXPA03001229A/es active IP Right Grant
- 2001-08-07 EP EP17153336.7A patent/EP3178934B1/fr not_active Expired - Lifetime
- 2001-08-07 SI SI200131070T patent/SI3178934T1/sl unknown
- 2001-08-07 NZ NZ535865A patent/NZ535865A/en not_active IP Right Cessation
- 2001-08-07 CA CA002418961A patent/CA2418961C/fr not_active Expired - Lifetime
- 2001-08-07 EP EP10184116.1A patent/EP2305817B1/fr not_active Expired - Lifetime
- 2001-08-07 EP EP01959598A patent/EP1309692B1/fr not_active Expired - Lifetime
-
2003
- 2003-02-07 NO NO20030614A patent/NO330903B1/no not_active IP Right Cessation
- 2003-02-07 HR HRP20030087AA patent/HRP20030087B1/xx not_active IP Right Cessation
-
2004
- 2004-08-06 US US10/912,994 patent/US20050002937A1/en not_active Abandoned
- 2004-10-28 US US10/975,883 patent/US7279157B2/en not_active Expired - Lifetime
- 2004-10-28 US US10/975,740 patent/US7063964B2/en not_active Expired - Lifetime
- 2004-10-28 US US10/975,708 patent/US7166285B2/en not_active Expired - Lifetime
-
2007
- 2007-01-29 US US11/668,256 patent/US7560247B2/en not_active Expired - Lifetime
-
2009
- 2009-03-11 CL CL2009000575A patent/CL2009000575A1/es unknown
- 2009-05-13 NL NL300390C patent/NL300390I2/nl unknown
- 2009-05-13 FR FR09C0021C patent/FR09C0021I2/fr active Active
- 2009-05-15 LT LTPA2009002C patent/LTC1309692I2/lt unknown
- 2009-06-09 CY CY20091100601T patent/CY1109149T1/el unknown
- 2009-06-12 CY CY2009007C patent/CY2009007I1/el unknown
- 2009-07-09 US US12/500,120 patent/US7887807B2/en not_active Expired - Fee Related
- 2009-07-10 LU LU91584C patent/LU91584I2/fr unknown
-
2010
- 2010-01-05 HK HK10100042.6A patent/HK1135991A1/zh not_active IP Right Cessation
- 2010-12-17 US US12/971,626 patent/US8084233B2/en not_active Expired - Fee Related
-
2011
- 2011-03-10 JP JP2011052971A patent/JP2011173884A/ja not_active Withdrawn
- 2011-10-04 NO NO2011023C patent/NO2011023I1/no not_active IP Right Cessation
- 2011-10-26 JP JP2011235204A patent/JP2012025779A/ja active Pending
- 2011-11-18 US US13/299,874 patent/US8329171B2/en not_active Expired - Lifetime
-
2012
- 2012-11-07 US US13/670,918 patent/US8703141B2/en not_active Expired - Fee Related
-
2014
- 2014-02-26 US US14/190,893 patent/US9409984B2/en not_active Expired - Fee Related
- 2014-09-22 JP JP2014192690A patent/JP6076303B2/ja not_active Expired - Lifetime
-
2016
- 2016-06-30 US US15/198,678 patent/US9676848B2/en not_active Expired - Lifetime
-
2017
- 2017-05-01 US US15/583,487 patent/US10259867B2/en not_active Expired - Fee Related
- 2017-05-18 CY CY20171100525T patent/CY1118901T1/el unknown
- 2017-12-05 CY CY20171101269T patent/CY1119650T1/el unknown
-
2018
- 2018-03-19 CY CY2018010C patent/CY2018010I1/el unknown
- 2018-03-20 LU LU00066C patent/LUC00066I2/fr unknown
- 2018-03-20 LT LTPA2018007C patent/LTC2305817I2/lt unknown
-
2019
- 2019-02-25 US US16/284,316 patent/US10519231B2/en not_active Expired - Fee Related
- 2019-10-02 CY CY20191101021T patent/CY1122505T1/el unknown
- 2019-11-07 US US16/677,120 patent/US11078267B2/en not_active Expired - Lifetime
-
2020
- 2020-01-10 LU LU00145C patent/LUC00145I2/fr unknown
- 2020-01-13 LT LTPA2020001C patent/LTPA2020001I1/lt unknown
- 2020-01-16 CY CY2020003C patent/CY2020003I1/el unknown
- 2020-03-11 NO NO2020005C patent/NO2020005I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR09C0021I2 (fr) | Anticorps, compositions, procedes anti-il-12 et leur utilisation | |
MA26348A1 (fr) | 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine substituees et leur utilisation | |
NO20025450L (no) | Ny farmasöytisk sammensetning | |
NO20023616L (no) | Ny anvendelse | |
DK1307744T3 (da) | Analyseapparat | |
DE60103472D1 (de) | Rohrschneider | |
EE200200680A (et) | Parendatud luminofoorid | |
DE60102651D1 (de) | Spannungsmessgerät | |
DE60144464D1 (de) | Probenentnehmer | |
DE60121497D1 (de) | Dynamisches Differenzkalorimeter | |
DE60132068D1 (de) | Empfangsgerät | |
DE60133976D1 (de) | Turbomaschinen | |
DE50102328D1 (de) | Feuchttücher (i) | |
DE60021770D1 (de) | Messkopf | |
DE60104363D1 (de) | Terphenylverbindungen | |
DE60138326D1 (de) | Abscheider | |
DE50104376D1 (de) | Düngerstreuer | |
DE60123315D1 (de) | Analysegerät | |
MA26894A1 (fr) | Agents antihypertenseurs et leur utilisation | |
FI20001992A (fi) | Impaktori | |
NO20023714D0 (no) | Ny koblingsprosess | |
FI20002308A0 (fi) | Saunan kiuas | |
ATA15512000A (de) | Wellenförmig gebogene gitterstruktur | |
ATA80162001A (de) | Sackkarren | |
ATA5852000A (de) | Messsonde |